Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SODIUM POLYSTYRENE SULFONATE - REFERENCE SPECTRUM (N/A)

SODIUM POLYSTYRENE SULFONATE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
FLURAZEPAM MONOHYDROCHLORIDE - REFERENCE SPECTRUM (N/A)

FLURAZEPAM MONOHYDROCHLORIDE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
PRAVASTATIN SODIUM - REFERENCE SPECTRUM (N/A)

PRAVASTATIN SODIUM - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
DIHYDROCODEINE HYDROGEN TARTRATE - REFERENCE SPECTRUM (N/A)

DIHYDROCODEINE HYDROGEN TARTRATE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
DIETHYLENE GLYCOL MONOETHYL ETHER - REFERENCE SPECTRUM (N/A)

DIETHYLENE GLYCOL MONOETHYL ETHER - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
ONDANSETRON  HYDROCHLORIDE DIHYDRATE CRS (220 MG)

ONDANSETRON HYDROCHLORIDE DIHYDRATE CRS (220 MG)

103639-04-9

DISCOVER
HUMAN ANTI-D IMMUNOGLOBULIN BRP (40 MG)

HUMAN ANTI-D IMMUNOGLOBULIN BRP (40 MG)

NA

DISCOVER
ROXITHROMYCIN FOR SYSTEM SUITABILITY CRS (10 MG)

ROXITHROMYCIN FOR SYSTEM SUITABILITY CRS (10 MG)

80214-83-1

DISCOVER
FLUTICASONE IMPURITY D CRS (15 MG)

FLUTICASONE IMPURITY D CRS (15 MG)

NA

DISCOVER
MOXONIDINE IMPURITY A CRS (15MG)

MOXONIDINE IMPURITY A CRS (15MG)

NA

DISCOVER
PRAVASTATIN IMPURITY A CRS (0.1 MG)

PRAVASTATIN IMPURITY A CRS (0.1 MG)

250737-12-3

DISCOVER
OXFENDAZOLE IMPURITY B CRS (25 MG)

OXFENDAZOLE IMPURITY B CRS (25 MG)

NA

DISCOVER